Literature DB >> 21193397

The multifunctional Ca2+/calmodulin-dependent kinase II delta (CaMKIIdelta) controls neointima formation after carotid ligation and vascular smooth muscle cell proliferation through cell cycle regulation by p21.

Weiwei Li1, Hui Li, Philip N Sanders, Peter J Mohler, Johannes Backs, Eric N Olson, Mark E Anderson, Isabella M Grumbach.   

Abstract

The multifunctional Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) promotes vascular smooth muscle (VSMC) proliferation. However, the signaling pathways mediating CAMKII-dependent proliferative effects in vivo are poorly understood. This study tested the hypothesis that CaMKIIδ mediates neointimal proliferation after carotid artery ligation by regulating expression and activity of cell cycle regulators, particularly at the G1/S checkpoint. Data herein indicate that 14 days after carotid ligation, C57Bl/6 mice developed a marked neointima with robust CaMKII protein expression. In particular, only the CaMKII isoform δ was increased as demonstrated by quantitative RT-PCR. Genetic deletion of CaMKII δ prevented injury-induced neointimal hyperplasia and cell proliferation in the intima and media. In ligated carotids of control mice, the proliferative cell cycle markers cdk2, cyclin E, and cyclin D1 were activated. In contrast, in CaMKIIδ(-/-) mice, we detected a reduction in proliferative cell cycle regulators as well as an increase in the cell cycle inhibitor p21. This expression profile was confirmed in cultured CaMKIIδ(-/-) VSMC, in which cdk2 and cdk4 activity was decreased. Toward understanding how CAMKIIδ affects p53, a transcriptional regulator of p21, we examined p53 pathway components. Our data indicate that p53 is elevated in CAMKIIδ(-/-) VSMC, whereas phosphorylation of the p53-specific E3 ligase, Mdm2, was decreased. In conclusion, CaMKII stimulates neointima proliferation after vascular injury by regulating cell proliferation through inhibition of p21 and induction of Mdm-2-mediated degradation of p53.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193397      PMCID: PMC3048686          DOI: 10.1074/jbc.M110.163006

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  Calcium/calmodulin-dependent protein kinase II-delta isoform regulation of vascular smooth muscle cell proliferation.

Authors:  Suzanne J House; Roman G Ginnan; Shayn E Armstrong; Harold A Singer
Journal:  Am J Physiol Cell Physiol       Date:  2007-01-31       Impact factor: 4.249

3.  KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels.

Authors:  Saman Rezazadeh; Thomas W Claydon; David Fedida
Journal:  J Pharmacol Exp Ther       Date:  2005-12-20       Impact factor: 4.030

4.  Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation.

Authors:  Kazuhiro Ishiguro; Todd Green; Joseph Rapley; Heather Wachtel; Cosmas Giallourakis; Aimee Landry; Zhifang Cao; Naifang Lu; Ando Takafumi; Hidemi Goto; Mark J Daly; Ramnik J Xavier
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.

Authors:  T A Morris; R J DeLorenzo; R M Tombes
Journal:  Exp Cell Res       Date:  1998-05-01       Impact factor: 3.905

6.  Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.

Authors:  D Rousseau; D Cannella; J Boulaire; P Fitzgerald; A Fotedar; R Fotedar
Journal:  Oncogene       Date:  1999-07-29       Impact factor: 9.867

7.  Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow.

Authors:  A Kumar; V Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

8.  Angiotensin II-induced Akt activation is mediated by metabolites of arachidonic acid generated by CaMKII-stimulated Ca2(+)-dependent phospholipase A2.

Authors:  Fang Li; Kafait U Malik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-06       Impact factor: 4.733

9.  p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy.

Authors:  M Ushio-Fukai; R W Alexander; M Akers; K K Griendling
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

10.  alpha-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression.

Authors:  Kaiyu Yuan; Leland W K Chung; Gene P Siegal; Majd Zayzafoon
Journal:  Lab Invest       Date:  2007-07-16       Impact factor: 5.662

View more
  38 in total

1.  CaMKII is essential for the proasthmatic effects of oxidation.

Authors:  Philip N Sanders; Olha M Koval; Omar A Jaffer; Anand M Prasad; Thomas R Businga; Jason A Scott; Patrick J Hayden; Elizabeth D Luczak; David D Dickey; Chantal Allamargot; Alicia K Olivier; David K Meyerholz; Alfred J Robison; Danny G Winder; Timothy S Blackwell; Ryszard Dworski; David Sammut; Brett A Wagner; Garry R Buettner; Robert M Pope; Francis J Miller; Megan E Dibbern; Hans Michael Haitchi; Peter J Mohler; Peter H Howarth; Joseph Zabner; Joel N Kline; Isabella M Grumbach; Mark E Anderson
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

2.  Ca2+/calmodulin-dependent protein kinase II-γ (CaMKIIγ) negatively regulates vascular smooth muscle cell proliferation and vascular remodeling.

Authors:  Fatima Z Saddouk; Li-Yan Sun; Yong Feng Liu; Miao Jiang; Diane V Singer; Johannes Backs; Dee Van Riper; Roman Ginnan; John J Schwarz; Harold A Singer
Journal:  FASEB J       Date:  2015-11-13       Impact factor: 5.191

3.  Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia.

Authors:  Manish Jain; Nirav Dhanesha; Prakash Doddapattar; Mehul R Chorawala; Manasa K Nayak; Anne Cornelissen; Liang Guo; Aloke V Finn; Steven R Lentz; Anil K Chauhan
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

4.  Vascular smooth muscle cell motility is mediated by a physical and functional interaction of Ca2+/calmodulin-dependent protein kinase IIδ2 and Fyn.

Authors:  Roman Ginnan; Xiaojing Zou; Paul J Pfleiderer; Melissa Z Mercure; Margarida Barroso; Harold A Singer
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

5.  The multifunctional Ca2+/calmodulin-dependent kinase II regulates vascular smooth muscle migration through matrix metalloproteinase 9.

Authors:  Jason A Scott; Litao Xie; Hui Li; Weiwei Li; Julie B He; Philip N Sanders; A Brent Carter; Johannes Backs; Mark E Anderson; Isabella M Grumbach
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

6.  MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells.

Authors:  Roman Ginnan; Li Yan Sun; John J Schwarz; Harold A Singer
Journal:  Biochem J       Date:  2012-05-15       Impact factor: 3.857

7.  Orai1-mediated I (CRAC) is essential for neointima formation after vascular injury.

Authors:  Wei Zhang; Katharine E Halligan; Xuexin Zhang; Jonathan M Bisaillon; José C Gonzalez-Cobos; Rajender K Motiani; Guoqing Hu; Peter A Vincent; Jiliang Zhou; Margarida Barroso; Harold A Singer; Khalid Matrougui; Mohamed Trebak
Journal:  Circ Res       Date:  2011-07-07       Impact factor: 17.367

8.  MicroRNAs are essential for stretch-induced vascular smooth muscle contractile differentiation via microRNA (miR)-145-dependent expression of L-type calcium channels.

Authors:  Karolina M Turczynska; Mardjaneh Karbalaei Sadegh; Per Hellstrand; Karl Swärd; Sebastian Albinsson
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

Review 9.  New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII).

Authors:  Adam G Rokita; Mark E Anderson
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

10.  Molecular determinants for cardiovascular TRPC6 channel regulation by Ca2+/calmodulin-dependent kinase II.

Authors:  Juan Shi; Naomi Geshi; Shinichi Takahashi; Shigeki Kiyonaka; Jun Ichikawa; Yaopeng Hu; Yasuo Mori; Yushi Ito; Ryuji Inoue
Journal:  J Physiol       Date:  2013-03-25       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.